Rocket Lab: Strong Execution but Valuation Stretched; WAIT Ahead of Neutron and SpaceX IPO

What happened

Rocket Lab posted record Q1 2026 revenue of $200M and a $2.2B backlog, but remains unprofitable with heavy reliance on ATM equity issuance. The stock trades at over 100x sales, pricing in Neutron success despite a recent tank test failure and schedule uncertainty. A Seeking Alpha article warns that the risk/reward is challenged, highlighting the upcoming SpaceX IPO as an alternative for space investors. The DeepValue report maintains a WAIT rating with a base case of $120, noting that while Space Systems growth is real, dilution and customer concentration are elevated. Investors should monitor Q2 revenue and MACH-TB 2.0 launch timing for signs of sustainable cash flow improvement.

Implication

Rocket Lab's strong revenue growth and backlog are overshadowed by a 100x+ sales valuation and reliance on ATM dilution. The company must demonstrate that it can convert its $2.2B backlog into cash without excessive share issuance. Key catalysts are Neutron's first launch (still high risk after tank failure) and the first MACH-TB 2.0 mission. Until then, the risk/reward is unfavorable, and a better entry point is around $95, as per the DeepValue base case. The upcoming SpaceX IPO could divert investor attention and increase competition for capital.

Thesis delta

The bearish Seeking Alpha article reinforces the DeepValue report's caution on valuation and Neutron risk. The report's WAIT rating remains appropriate, with no material change in thesis. The key new consideration is the potential overhang from SpaceX's IPO, which could limit upside.